Does Rallies show Form 4 insider transactions for CDNA?

Yes. Rallies tracks CDNA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CDNA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CDNA. It does not provide personalized investment advice.

CDNA (CareDx, Inc.) Stock Analysis - Insider Trades

CareDx, Inc. (CDNA) is a publicly traded Healthcare sector company. As of May 21, 2026, CDNA trades at $21.15 with a market cap of $1.06B and a P/E ratio of -132.13. CDNA moved +2.92% today. Year to date, CDNA is +6.76%; over the trailing twelve months it is +19.22%. Its 52-week range spans $10.96 to $32.97. Analyst consensus is buy with an average price target of $24.73. Rallies surfaces CDNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CDNA stock inside the company?

Recent CDNA insider activity includes Novack Jeffrey Adam sold 2.69K, Hanna John Walter JR sold 10.28K, Novack Jeffrey Adam sold 4.44K, Hanna John Walter JR sold 19.28K, and Hanna John Walter JR sold 200. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CDNA Key Metrics

Key financial metrics for CDNA
Metric	Value
Price	$21.15
Market Cap	$1.06B
P/E Ratio	-132.13
EPS	$-0.16
Dividend Yield	0.00%
52-Week High	$32.97
52-Week Low	$10.96
Volume	0
Avg Volume	0
Revenue (TTM)	$412.82M
Net Income	$-8.19M
Gross Margin	0.00%

Recent CDNA Insider Trades

Novack Jeffrey Adam sold 2.69K (~$55.58K) on May 5, 2026.
Hanna John Walter JR sold 10.28K (~$217.16K) on Apr 16, 2026.
Novack Jeffrey Adam sold 4.44K (~$91.29K) on Feb 3, 2026.
Hanna John Walter JR sold 19.28K (~$408.02K) on Jan 22, 2026.
Hanna John Walter JR sold 200 (~$4.20K) on Jan 21, 2026.

Latest CDNA News

CareDx Q1 Revenue Up 39% to $118M and Acquires Naveris for $260M — Apr 29, 2026
CareDx Sells Lab Products Business for $170M, Q1 Revenue Rises 39% — Apr 15, 2026
CareDx Q4 Revenue Jumps 25% to $108M, Outlines Transplant+ Roadmap — Mar 7, 2026
CareDx Launches VANTx AI Platform Leveraging Llama 3 for Transplant Analytics — Mar 5, 2026
CareDx Reports Q4 Revenue Growth and European Launch of AlloSure Test — Feb 25, 2026

CDNA Analyst Consensus

6 analysts cover CDNA: 0 strong buy, 2 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $24.73.

Common questions about CDNA

Who is trading CDNA stock inside the company?: Recent CDNA insider activity includes Novack Jeffrey Adam sold 2.69K, Hanna John Walter JR sold 10.28K, Novack Jeffrey Adam sold 4.44K, Hanna John Walter JR sold 19.28K, and Hanna John Walter JR sold 200. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CDNA?: Yes. Rallies tracks CDNA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CDNA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CDNA. It does not provide personalized investment advice.